Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo

NCT05498467 is registered in ClinicalTrials.gov with Herlev and Gentofte Hospital as lead sponsor.

NCT NCT05498467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05498467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo
Lead sponsor
Herlev and Gentofte Hospital
Phase
Phase 3
Overall status
Completed
Start date
October 11, 2022
Completion date
August 1, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic contact dermatitis